Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration

References

• Noble S, Balfour JA. (1996). Meloxicam. Drugs, 51:424–30; discussion 431.
   PubMed Web of Science ®Google Scholar
• Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res, 44:423–433.
   PubMed Web of Science ®Google Scholar
• Seedher N, Bhatia S. (2003). Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech, 4:E33.
   PubMedGoogle Scholar
• Bock T, Saegmueller P, Sieger P, Tuerck B. Meloxicam for oral administration. DE: Boehringer Ingelheim Pharma KG, Ingelheim (DE), 2005.
   Google Scholar
• Alayoubi A, Satyanarayanajois SD, Sylvester PW, Nazzal S. (2012). Molecular modelling and multisimplex optimization of tocotrienol-rich self emulsified drug delivery systems. Int J Pharm, 426:153–161.
   PubMedGoogle Scholar
• Khoo SM, Porter JH, Edwards GA, Charman WN. (1998). Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci, 87:1538–1541.
   PubMed Web of Science ®Google Scholar
• Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA et al. (1998). Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci, 87:164–169.
   PubMed Web of Science ®Google Scholar
• Klauser RM, Irschik H, Kletzmayr J, Sturm I, Brunner W, Woloszczuk W et al. (1997). Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter? Transplant Proc, 29:3137–3140.
   PubMed Web of Science ®Google Scholar
• MacGregor KJ, Embleton JK, Lacy JE, et al. (1997) Influence of lipolysis on drug absorption from the gastro-intestinal tract. Advanced Drug Delivery Reviews, 25:33–46.
   Web of Science ®Google Scholar
• Nazzal S, Wang Y. (2001). Characterization of soft gelatin capsules by thermal analysis. Int J Pharm, 230:35–45.
   PubMed Web of Science ®Google Scholar
• Lu Y, Mei Y, Drechsler M, Ballauff M. (2006). Thermosensitive core-shell particles as carriers for ag nanoparticles: modulating the catalytic activity by a phase transition in networks. Angew Chem Int Ed Engl, 45:813–816.
   PubMed Web of Science ®Google Scholar
• Nazzal S, Nutan M, Palamakula A, Shah R, Zaghloul AA, Khan MA. (2002). Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: effect of formulation ingredients. Int J Pharm, 240:103–114.
   PubMed Web of Science ®Google Scholar
• Pather SI, Gupte SV, Khankari RK, et al. Microemulsions as solid dosage forms for oral administration. Cima Labs Inc., 2001.
   Google Scholar
• Agarwal V, Siddiqui A, Ali H, Nazzal S. (2009). Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int J Pharm, 366:44–52.
   PubMed Web of Science ®Google Scholar
• Nazzal S, Khan MA. (2006). Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int J Pharm, 315:110–121.
   PubMed Web of Science ®Google Scholar
• Cannon JB. (2005). Oral solid dosage forms of lipid-based drug delivery systems. American Pharmaceutical Review, 8:108–115.
   Google Scholar
• Jannin V, Chambin O. Self emulsifying drug delivery systems. (2005). STP Pharma Pratique, 15:247–254.
   Google Scholar
• Yang KY, Glemza R, Jarowski CI. (1979). Effects of amorphous silicon dioxides on drug dissolution. J Pharm Sci, 68:560–565.
   PubMed Web of Science ®Google Scholar
• Liao CC, Jarowski CI. (1984). Dissolution rates of corticoid solutions dispersed on silicas. J Pharm Sci, 73:401–403.
   PubMed Web of Science ®Google Scholar
• Spireas S, Sadu S. (1998). Enhancement of prednisolone dissolution properties using liquisolid compacts. International Journal of Pharmaceutics, 166:177–188.
   Web of Science ®Google Scholar
• Carr RL. Evaluating flow properties of solids. (1965) Chemical Engineering Journal, 18:163–168.
   Google Scholar
• Eglitis RI, Kuklja MM, Kotomin EA, et al. Structure and physicochemical properties of meloxicam, a new NSAID. (1996). European Journal of Pharmaceutical Sciences, 4:175–187.
   Web of Science ®Google Scholar
• Yuan Y, Li SM, Mo FK, Zhong DF. (2006). Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm, 321:117–123.
   PubMed Web of Science ®Google Scholar
• Nazzal S, Zaghloul A-A, Khan MA. Effect of Extragranular Microcrystalline Cellulose on Compaction, Surface Roughness, and In Vitro Dissolution of a Self-Nanoemulsified Solid Dosage Form of Ubiquinone. Pharmaceutical Technology, 2002.
   Google Scholar
• Kuminek G, Kratz JM, Ribeiro R, Kelmann RG, de Araújo BV, Teixeira HF et al. (2009). Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm, 378:146–148.
   PubMed Web of Science ®Google Scholar
• Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF et al. (2010). Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact, 183:317–326.
   PubMed Web of Science ®Google Scholar
• Ye X, Tang M, Liu J, Wang X, Ma L, Zheng H et al. (2011). Development and validation of a UPLC-MS/MS method for quantification of SKLB010, an investigational anti-inflammatory compound, and its application to pharmacokinetic studies in beagle dogs. J Pharm Biomed Anal, 56:366–372.
   PubMed Web of Science ®Google Scholar
• Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C et al. (1998). Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos, 26:576–584.
   PubMed Web of Science ®Google Scholar
• Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65–73.
   PubMed Web of Science ®Google Scholar